Hematologic Oncology | Specialty

The OncLive Hematology Oncology condition center page is a comprehensive resource for clinical news and expert insights on various hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms, multiple myeloma, and much more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in hematologic cancers.

Optimizing Therapy for Patients With Multiple Myeloma

August 13th 2019

Navigating Through Testicular Cancer Treatment

August 13th 2019

CML Paradigm Transforms With New Treatments, Potential for TKI Discontinuation

August 9th 2019

Jorge Cortes, MD, discusses frontline advances, discontinuation, and remaining challenges in the chronic myeloid leukemia paradigm.

Dr. Chao on Minimal Residual Disease in ALL

August 9th 2019

Nelson Jen An Chao, MD, professor of medicine, Donald D. and Elizabeth G. Cooke Cancer Research Professor, chief, Division of Cell Therapy in the Department of Medicine, Duke Cancer Institute, discusses minimal residual disease (MRD) in acute lymphoblastic leukemia (ALL).

Experts Discuss Highly Anticipated Study Results Across Tumor Types

August 5th 2019

OncLive interviewed experts at the State of the Science Summits in July 2019 on highly anticipated clinical trial results across tumor types.

NCCN Guidelines Set New Pace for Pediatric ALL

August 4th 2019

With the recent publication of an inaugural set of guidelines for treatment of pediatric acute lymphoblastic leukemia, the National Comprehensive Cancer Network seeks to introduce standards to a branch of care long dominated by clinical trial protocols.

Dr. Straus on the 3-Year Results of the ECHELON-1 Study in Hodgkin Lymphoma

July 31st 2019

David J. Straus, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the 3-year follow-up results of the ECHELON-1 study, which examines brentuximab vedotin with chemotherapy for stage III/IV classical Hodgkin lymphoma.

Dr. Neelapu on Third-Line CAR T-Cell Therapy in Large B-Cell Lymphoma

July 31st 2019

Sattva Neelapu, MD, discusses the use of CAR T-cell therapy in the third-line setting for patients with large B-cell lymphoma.

Dr. Fertrin on the Potential of Fostamatinib in Chronic ITP

July 30th 2019

Kleber Y. Fertrin, MD, PhD, assistant professor, University of Washington School of Medicine, and hematology oncologist, Seattle Cancer Care Alliance, discusses the potential of fostamatinib (Tavalisse) in the treatment of patients with chronic immune thrombocytopenia (ITP).

Looking Ahead in Treating Follicular Lymphoma

July 29th 2019

Emergent Therapies for Follicular Lymphoma

July 29th 2019

Immunotherapy for Follicular Lymphoma

July 29th 2019

Potential of R-Squared Regimen in Treating Follicular Lymphoma

July 29th 2019

Strategies for Sequencing Agents in FL

July 29th 2019

PI3 Kinase Inhibitors for Third-Line Therapy in FL

July 29th 2019

Treating Relapse in Follicular Lymphoma

July 29th 2019

Follicular Lymphoma: Progression of Disease

July 29th 2019

Maintenance Therapy for Follicular Lymphoma

July 29th 2019

PET Scan After Frontline Therapy for FL

July 29th 2019

GALLIUM Phase III Trial in Follicular Lymphoma

July 29th 2019